CTI 016
Alternative Names: CTI-016Latest Information Update: 28 Sep 2024
At a glance
- Originator Cellics Therapeutics
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections(Prevention) in USA
- 28 Sep 2024 No recent reports of development identified for preclinical development in Pseudomonal-infections(Prevention) in USA
- 20 Aug 2020 CTI 016 is available for licensing as of 20 Aug 2020. https://cellics.com/full-pipeline/